Supernus Up on Report of Progress With ADHD Remedy

Supernus Pharmaceuticals  (SUPN) – Get Report shares jumped on Wednesday following the drugmaker concentrated on the central

Supernus Pharmaceuticals  (SUPN) – Get Report shares jumped on Wednesday following the drugmaker concentrated on the central nervous system documented progress in a Phase 3 examine of an attention-deficit-hyperactivity-disorder drug.